CMPX
Compass TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The constructive interpretation is that the April BTC update showed statistically significant ORR and PFS benefit, while the May 5 earnings release reiterated a planned FDA meeting, possible BLA timing later in 2026, and $195 million of cash expected to fund operations into 2028 [#8-K-2026-05-05] [#10-Q-2026-05-05]. If FDA focuses on the totality of efficacy and the crossover issue is manageable, the post-collapse equity value leaves room for recovery.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta 0.0.
What can break
CMPX remains a low-coverage small-cap biotech, which increases volatility and lowers confidence that consensus targets fully reflect the latest clinical debate.
Momentum
35
Value
41
Sentiment
47
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.90 · Bull $4.50 · Bear $0.80
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $13.57
Why
Momentum35 · Δ7d +3.1
Value41 · Δ7d +0.1
Sentiment47 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
35
34% active weight
Current posture
7d trendFlat
Δ7d
+3.1
Δ21d
-7.1
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
47
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+22.0
Why this grade
Composite grade D. Momentum 34.9 / Value 41.1 / Sentiment 46.6
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$399.8M
Beta
1.27
Shares Out
177.86M
P/E (TTM) · Derived
-6.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-7.27
Rev YoY
-100.0%
EPS YoY
-10.9%
Gross Margin
-
Op Margin
-7273.4%
Net Debt
-
Current Ratio
17.82
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology